secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058157
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q3 net loss $38.6M; cash $452.6M; ziftomenib trial enrollment on track for mid-2024
--------------------------------------------------------------------------------

- Net loss $38.6M vs $35.5M YoY; R&D $29.3M; cash $452.6M provides runway to mid-2026.
- Enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete 85 patients by mid-2024.
- Preliminary data from 20 patients in KOMET-007 combination trial (ziftomenib + venetoclax/azacitidine or 7+3) expected early Q1 2024.
- First patient dosed in FIT-001 trial of next-gen FTI KO-2806; collaboration with Mirati for combo with adagrasib in KRAS G12C-mutated NSCLC.
- Brian Powl appointed Chief Commercial Officer in August 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/0000950170-23-058157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/kura-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer